Table 4.
Concentrations of imatinib, dasatinib or nilotinib in human plasma of CML patients (n=18).
| Drug | Sample ID | Time interval (h)a | Dose (mg/d) | Conc. (ng/mL) |
|---|---|---|---|---|
| Imatinib | 1 | 2.7 | 400 | 2899.6 |
| 2 | 6.6 | 400 | 2517.2 | |
| 3 | 8.7 | 400 | 2366.2 | |
| 4 | 14.9 | 400 | 2196.0 | |
| 5 | 15.2 | 400 | 1931.5 | |
| 6 | 16.2 | 400 | 1194.1 | |
| 7 | 22.2 | 400 | 664.3 | |
| 8 | 25.7 | 400 | 400.1 | |
| Dasatinib | 1 | 7.8 | 100 | 16.8 |
| 2 | 5.3 | 100 | 94.5 | |
| 3 | 1.2 | 100 | 157.6 | |
| 4 | 3.6 | 100 | 132.9 | |
| 5 | 12.1 | 100 | 13.2 | |
| Nilotinib | 1 | 1.4 | 600 | 2535.3 |
| 2 | 1.8 | 600 | 3130.4 | |
| 3 | 4.4 | 600 | 2437.6 | |
| 4 | 5.0 | 600 | 1920.8 | |
| 5 | 6.3 | 600 | 1495.8 |
a
The time interval between the last medication and sampling.